Headquartered in Cambridge, MA Fiscal year ends December NASDAQ: EDIT editasmedicine.com
Editas Medicine is a clinical-stage gene editing company focused on developing transformative in vivo medicines using CRISPR genome editing technology for serious diseases. The company is the exclusive licensee of the Broad Institute's Cas12a patent estate and the Broad Institute and Harvard University's Cas9 patent estates for human medicines. Its lead program, EDIT-401, targets hyperlipidemia and Heterozygous Familial Hypercholesterolemia (HeFH), a condition affecting an estimated 1.2 million people in the United States. Editas previously discontinued its reni-cel program in December 2024 and has since refocused its pipeline and resources on EDIT-401. The company generates revenue primarily through collaboration agreements, including a partnership with Bristol-Myers Squibb. Editas aims to discover, develop, manufacture, and commercialize durable, precision in vivo gene editing medicines. Updated
CRISPR Therapeutics owns the only approved gene therapy of its kind, yet the stock sits far below where Wall Street thinks it belongs. One analyst sees a path to gains that would…
Moderna's stock just surged in a way that transforms the company from a cash-burning vaccine maker into a serious acquirer, and four biotech targets already sit within striking range of its newly…
Turning a $10,000 investment into $1 million represents a financial dream for many — a 100x return that would require an annualized growth rate of approximately 63% over a decade. This level…
There has been a noticeable shift in the stock market over the last two months. Investors are moving away from former high-flying large- and mega-cap stocks into discounted small-cap names that the…
Market pullbacks can make nervous investors leery of investing in industries that are more speculative. Wall Street still has big expectations for Vir Biotechnology.
Why did Ginkgo Bioworks CEO Jason Kelly chop 20 million shares from his stake in the company? Is no turnaround for the shares coming?
Thursday's top analyst upgrades and downgrades included Albemarle, Arm, CrowdStrike, Dow, Fortinet, Hudson Pacific Properties, Lithium Americas, LyondellBasell Industries, Match, Palo Alto Networks, Pinterest, Sibanye-Stillwater, Uber Technologies and Vestis.
Monday's top analyst upgrades and downgrades included AbbVie, Adobe, Advance Auto Parts, Anheuser-Busch InBev, Bumble, Fortinet, Nike and Palo Alto Networks.
Tuesday's top analyst upgrades and downgrades included Bill, Carnival, CenterPoint Energy, Editas Medicine, International Paper, Oracle, Palantir Technologies, Petrobras, SentinelOne, Trade Desk, Valvoline and Walmart.
Tuesday's top analyst upgrades and downgrades included Advanced Micro Devices, American Eagle Outfitters, Azek, Bausch Health, Coinbase Global, Dell Technologies, Fidelity National Information Services, Invesco, Marathon Petroleum, Netflix, New Residential Investment, Spotify…
Tuesday afternoon's analyst upgrades and downgrades included CRISPR, Editas, Esperion Therapeutics, Marriott Penn National Gaming and more.
Friday afternoon's analyst upgrades and downgrades included Barrick Gold, Canadian National Railway, Community Health Systems, Editas Medicine, Intellia Therapeutics, Newmont and Salesforce.com.
Friday’s top analyst upgrades and downgrades included American Tower, Best Buy, Beyond Meat, Editas Medicine, Freeport McMoRan, First Solar and UnitedHealth.
24/7 Wall St. looks at some big analyst upgrades and downgrades that we have seen so far on Friday, including Caesars Entertainment, Coinbase Global, Editas Medicine and Wynn Resorts.
24/7 Wall St. looks at some big analyst upgrades and downgrades that we have seen so far on Thursday, including Bath & Body Works, Editas Medicine, GoDaddy, PetMed Express and Qorvo.
Editas Medicine is a clinical-stage gene editing company focused on developing transformative in vivo medicines using CRISPR genome editing technology for serious diseases.
The Wall Street consensus 12-month price target for EDIT is $5.90.
